Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW

Exclusion Criteria

• •Second malignancy in the breast and other organs
• •Pregnant or breastfeeding patients
• •Planned sentinel lymph node marking using patent blue
• •Previous radiation therapy in the area to be examined
• •Known or suspected hypersensitivity to the study medication (according to IMPD / SmPC) or other immunoglobulins
• •Currently after neoadjuvant (primarily systemic) chemotherapy and anti-hormone therapy
• •Immunotherapy (e.g. monoclonal antibodies, cytokines or signal transduction inhibitors) in the last 28 days prior to the declaration of consent
• •Previous therapy with bevacizumab
• •Planned reconstruction in the breast to be examined
• •Previous surgery within the last 28 days prior to the declaration of consent
• •Non-healing wounds, ulcers or broken bones within the last 28 days prior to giving informed consent
• •Patients with ileus within the last 28 days prior to the declaration of consent
• •Non-adjustable hypertension (\> 145/90 mmHg) despite optimal drug therapy
• •Insufficient kidney function (serum creatinine\> 1.5 x upper limit of the normal range)
• •Current or recent treatment with another investigational drug in another clinical trial within 28 days of informed consent
• •Potentially fertile women without adequate contraception. Safe contraceptive measures are procedures with a Pearl index of ≤ 1%
• •Patients with other serious illnesses that pose an unreasonable risk for participating in the study
• •Persons who are in a dependent / employment relationship with the sponsor or investigator
• •Persons who are to be or are to be accommodated in an institution due to a court or official order